---
title: 'Type I inhibitors of tropomyosin receptor kinase (Trk): a 2020-2022 patent
  update'
date: '2023-09-22'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37735897/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20230922181057&v=2.17.9.post6+86293ac
source: heidelberg[Affiliation]
description: 'INTRODUCTION: Trk inhibitors are significant in the realm of personalized
  medicine as they target specific genetic alterations, such as NTRK gene fusions,
  leading to improved treatment outcomes for cancer patients. By tailoring the treatment
  to the genetic characteristics of the tumor rather than the tumor type, Trk inhibitors
  offer the potential for more effective and precise therapies, resulting in enhanced
  response rates and prolonged survival for patients with NTRK fusion-positive ...'
disable_comments: true
---
INTRODUCTION: Trk inhibitors are significant in the realm of personalized medicine as they target specific genetic alterations, such as NTRK gene fusions, leading to improved treatment outcomes for cancer patients. By tailoring the treatment to the genetic characteristics of the tumor rather than the tumor type, Trk inhibitors offer the potential for more effective and precise therapies, resulting in enhanced response rates and prolonged survival for patients with NTRK fusion-positive ...